0.28
0.28 (0%)
As of Apr 17, 2025
Igc Pharma, Inc. [IGC]
Source:
Company Overview
IGC Pharma, a clinical-stage company developing treatments for Alzheimer’s disease, is committed to transforming patient care by offering faster-acting and more effective solutions. Our lead drug, IGC-AD1, embodies this vision by tackling a critical challenge – managing agitation in Alzheimer’s dementia.
| Country | United States |
| Headquarters | potomac, maryland |
| Phone Number | (301) 983-0998 |
| Industry | manufacturing |
| CEO | Ram Mukunda |
| Website | www.igcpharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.3 |
| Operating Profit | $-1.9 |
| Net Income | $-1.8 |
| Net Cash | $-0.7 |
Profit Ratios
| Gross Margin | $0.1 |
| Operating Margin | -730.7 |
| Profit as % of Revenues | -5.7% |
| Profit as % of Assets | -19.3% |
| Profit as % of Stockholder Equity | -29.2% |
Management Effectiveness
| Return on Equity | -29.2% |
| Return on Assets | -20.2% |
| Turnover Ratio | 2.7% |
| EBITA | $-1.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $9.1 |
| Total Liabilities | $2.8 |
| Operating Cash Flow | $-4.1 |
| Investing Cash Flow | $-0.3 |
| Financing Cash Flow | $3.6 |
